Inactive Instrument

Press Releases Jounce Therapeutics, Inc.

Equities

JNCE

US4811161011

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

JOUNCE THERAPEUTICS, INC. : Termination of a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Material Modification to Rights of Security Holders, Changes in Control or Registrant, Change in Directors or Principal Officers, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year (form 8-K)	23-05-04	AQ
Jounce Therapeutics Announces Closing of Tender Offer	23-05-03	AQ
Termination of Proposed Business Combination of Jounce Therapeutics, Inc. and Redx Pharma plc	23-04-03	AQ
JOUNCE THERAPEUTICS, INC. : Change in Directors or Principal Officers (form 8-K)	23-03-30	AQ
Jounce Therapeutics : NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION - Form 8-K	23-03-27	PU
JOUNCE THERAPEUTICS, INC. : Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Costs Associated with Exit or Disposal Activities, Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)	23-03-27	AQ
Jounce Therapeutics Enters Into Agreement to Be Acquired by Concentra Biosciences for $1.85 in Cash per Share Plus Contingent Value Rights	23-03-27	AQ
Jounce Therapeutics Announces Results from Pre-Planned Data Review of INNATE Phase 2 Trial of JTX-8064 and Pimivalimab Demonstrating Deep and Durable Responses in Platinum Resistant Ovarian Cancer	23-03-16	AQ
JOUNCE THERAPEUTICS, INC. : Other Events, Financial Statements and Exhibits (form 8-K)	23-03-15	AQ
Jounce Therapeutics Confirms Receipt of Unsolicited Proposal from Concentra Biosciences	23-03-14	AQ
JOUNCE THERAPEUTICS, INC. : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)	23-03-13	AQ
JOUNCE THERAPEUTICS, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-K)	23-03-10	AQ
JOUNCE THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Jounce Therapeutics, Inc. - JNCE	23-02-27	BU
Jounce Therapeutics : SHAREHOLDER'S IRREVOCABLE UNDERTAKING - Form 8-K	23-02-23	PU
JOUNCE THERAPEUTICS, INC. : Entry into a Material Definitive Agreement, Costs Associated with Exit or Disposal Activities, Unregistered Sale of Equity Securities, Change in Directors or Principal Officers, Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)	23-02-23	AQ
Redx and Jounce Announce Recommended Business Combination	23-02-23	AQ
Jounce Therapeutics Announces Restructuring	23-02-22	AQ
JOUNCE THERAPEUTICS, INC. : Change in Directors or Principal Officers, Other Events, Financial Statements and Exhibits (form 8-K)	23-01-20	AQ
JOUNCE THERAPEUTICS, INC. : Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing (form 8-K)	23-01-05	AQ
JOUNCE THERAPEUTICS, INC. : Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)	22-12-27	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Jounce Therapeutics, Inc.

Equities

JNCE

US4811161011

Press Releases

Filters